ArticleBreast cancer research : BCR2015
Lectin RCA-I specifically binds to metastasis-associated cell surface glycans in triple-negative breast cancer.
Article in Breast cancer research : BCR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 70 citations in OpenAlex.
- Applications of Plant Lectins in Detection and Targeted Therapy of Urological Cancers.Drug design, development and therapy · 2026Review
- Fucosylated N-Glycan Landscape of Triple-Negative Breast Cancer.Molecular cancer research : MCR · 2025Article
- Monosaccharide Binding to Synthetic Carbohydrate Receptor Microarrays.The journal of physical chemistry. C, Nanomaterials and interfaces · 2025Article
- Targeting the cancer glycocalyx in salivary duct carcinoma: tumor-associated mucin 1 (Tn-MUC1) as a novel cell surface marker.The journal of pathology. Clinical research · 2025Article
- Deciphering disease through glycan codes: leveraging lectin microarrays for clinical insights.Acta biochimica et biophysica Sinica · 2024Review
- A molecular approach to triple-negative breast cancer: targeting the Notch signaling pathway.Einstein (Sao Paulo, Brazil) · 2024Review
- Lectins as a promising therapeutic agent for breast cancer: A review.Breast disease · 2024Review
- MATTE: a pipeline of transcriptome module alignment for anti-noise phenotype-gene-related analysis.Briefings in bioinformatics · 2023Article
- Anticancer Activity of Mannose-Specific Lectin, BPL2, from Marine Green AlgaMarine drugs · 2022Article
- Analysis of Minor Proteins Present in Breast Milk by Using WGA Lectin.Children (Basel, Switzerland) · 2022Article
- Article
- Application of Isothermal Signal Amplification Technique in the Etiological Diagnosis of Gonorrhea and Drug Resistance Gene Detection.Computational and mathematical methods in medicine · 2022Article
- Comprehensive analysis of lectin-glycan interactions reveals determinants of lectin specificity.PLoS computational biology · 2021Article
- The State of the Art of Theranostic Nanomaterials for Lung, Breast, and Prostate Cancers.Nanomaterials (Basel, Switzerland) · 2021Review
- Article
- Extracellular Matrix Proteins Confer Cell Adhesion-Mediated Drug Resistance Through Integrin αFrontiers in cell and developmental biology · 2021Article
- Comprehensive role of prostate-specific antigen identified with proteomic analysis in prostate cancer.Journal of cellular and molecular medicine · 2020Article
- A lectin-based glycomic approach identifies FUT8 as a driver of radioresistance in oesophageal squamous cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2020Article
- Application of electrochemical biosensors in tumor cell detection.Thoracic cancer · 2020Review
- Application of Lectin Microarrays for Biomarker Discovery.ChemistryOpen · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
introductionTriple-negative breast cancer (TNBC) patients often face a high risk of early relapse characterized by extensive metastasis. Previous works have shown that aberrant cell surface glycosylation is associated with cancer metastasis, suggesting that altered glycosylations might serve as diagnostic signatures of metastatic potential. To address this question, we took TNBC as an example and analyzed six TNBC cell lines, derived from a common progenitor, that differ in metastatic potential.
methodsWe used a microarray with 91 lectins to screen for altered lectin bindings to the six TNBC cell lines. Candidate lectins were then verified by lectin-based flow cytometry and immunofluorescent staining assays using both TNBC/non-TNBC cancer cells. Patient-derived tissue microarrays were then employed to analyze whether the staining of Ricinus communis agglutinin I (RCA-I), correlated with TNBC severity. We also carried out real-time cell motility assays in the presence of RCA-I. Finally, liquid chromatography-mass spectrometry/tandem spectrometry (LC-MS/MS) was employed to identify the membrane glycoproteins recognized by RCA-I.
resultsUsing the lectin microarray, we found that the bindings of RCA-I to TNBC cells are proportional to their metastatic capacity. Tissue microarray experiments showed that the intensity of RCA-I staining is positively correlated with the TNM grades. The real-time cell motility assays clearly demonstrated RCA-I inhibition of adhesion, migration, and invasion of TNBC cells of high metastatic capacity. Additionally, a membrane glycoprotein, POTE ankyrin domain family member F (POTEF), with different galactosylation extents in high/low metastatic TNBC cells was identified by LC-MS/MS as a binder of RCA-I.
conclusionsWe discovered RCA-I, which bound to TNBC cells to a degree that is proportional to their metastatic capacities, and found that this binding inhibits the cell invasion, migration, and adhesion, and identified a membrane protein, POTEF, which may play a key role in mediating these effects. These results thus indicate that RCA-I-specific cell surface glycoproteins may play a critical role in TNBC metastasis and that the extent of RCA-I cell binding could be used in diagnosis to predict the likelihood of developing metastases in TNBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.